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Sperm DNA fragmentation (sDF) is an important reproductive problem, associated to
an increased time-to-pregnancy and a reduced success rate in natural and in vitro
fertilization. sDF may virtually originate at any time of sperm’s life: in the testis, in the
epididymis, during transit in the ejaculatory ducts and even following ejaculation. Studies
demonstrate that an apoptotic pathway, mainly occurring in the testis, and oxidative
stress, likely acting in the male genital tract, are responsible for provoking the DNA
strand breaks present in ejaculated spermatozoa. Although several pharmacological
anti-oxidants tools have been used to reduce sDF, the efficacy of this type of therapies is
questioned. Clearly, anti-apoptotic agents cannot be used because of the ubiquitous
role of the apoptotic process in the body. A notable exception is represented by
Follicle-stimulating hormone (FSH), which regulates testis development and function and
has been demonstrated to exert anti-apoptotic actions on germ cells. Here, we review the
existing clinical studies evaluating the effect of FSH administration on sDF and discuss
the possible mechanisms through which the hormone may reduce sDF levels in infertile
subjects. Although there is evidence for a beneficial effect of the hormone on sDF, further
studies with clear and univocal patient inclusion criteria, including sDF cut-off levels and
considering the use of a pharmacogenetic approach for patients selection are warranted
to draw firm conclusions.
Keywords: testis apoptosis, DNA fragmentation, human spermatozoa, oxidative stress, follicle-stimulating
hormone
INTRODUCTION
FSH (follicle-stimulating hormone or follitropin) is the main hormone regulating the development
and the functions of male and female gonads. It is a glycoprotein heterodimer consisting of
two chains, α (92 amino-acids) and β (111 amino-acids) which are coupled by a non-covalent
bond. The hormone acts by binding its receptor (FSHR) which belongs to the superfamily of
the seven transmembrane domain G-protein-coupled receptors and is expressed in the gonads.
After binding to FSHR, FSH activates the cAMP-protein kinase A cascade, which regulates
gene expression through phosphorylation of CREB transcription factors [for a comprehensive
review on FSR receptor signaling see (1)]. The action of FSH is influenced by the presence
of both polymorphisms of FSHR, affecting the sensitivity of the receptors to the hormone (2),
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and the β chain of the hormone, which is associated with
significantly lower serum FSH levels (3). FSHR and FSHβ
polymorphisms influence the response to treatment with FSH in
both women (4, 5) and men (6). In particular, in the adult testis,
FSH regulates spermatogenesis by acting on Sertoli cells and there
is evidence that FSHR polymorphisms are associated with male
infertility (7).
FSH is essential for induction of qualitative and quantitative
maintenance of spermatogenesis (8), as also demonstrated by
studies on FSHR KO animals, which present severe disturbances
of testicular function, including small testis and aberrant
gametogenesis (9–11). Besides hypogonadotropic hypogonadic
men (12), highly purified or recombinant FSH has been proposed
for the treatment of infertile normogonadotropic men with
idiopathic oligozoospermia or oligoasthenoteratozoospermia
(OAT). In human, several trials using FSH to treat men with
alterations of spermatogenesis, in particular OATmen, have been
published. Although many of these studies report improvement
of sperm parameters, such as concentration and motility, the
efficacy of FSH treatment for OAT subjects remains controversial
(6, 13). Even more controversy exists regarding the effect of
FSH treatment on sperm morphology (14–17). Controversy may
depend on heterogeneity of the study characteristics, in particular
patient inclusion criteria (including FSH basal levels, FSHβ and
FSHR genotypes), the dose and the molecule of administered
FSH, the length of the treatment and the presence of non-
responding men (18). Despite such controversy, a Cochrane
meta-analysis (19) including only randomized control trials
in which gonadotrophins were compared with placebo or no
treatment, suggests a beneficial effect of FSH treatment on
live birth and pregnancy after natural conception in men with
idiopathic male factor subfertility, but no significant effects
after assisted reproduction techniques (ARTs). A more recent
meta-analysis (20) evaluating 15 controlled clinical studies [with
broader inclusion criteria respect to (19)] with overall 614 men
treated with FSH vs. 661 treated with placebo or untreated,
confirms the improvement of spontaneous pregnancy and reveals
a significant effect also after ARTs, which is independent on
the ART methodology. Interestingly, 11 studies evaluated also
sperm parameters after FSH treatment and the meta-analysis of
these studies indicated that the treatment induced a significant
increase of sperm concentration (although with a high degree of
heterogeneity of the studies) and a trend to a better progressive
sperm motility. However, a meta-regression analysis of the same
studies showed no significant correlation between pregnancy rate
and sperm parameters (concentration, progressive motility) (20)
in line with previous studies demonstrating the poor predictive
value of semen parameters for attainment of pregnancy (21, 22).
Thus, the improvement of pregnancy rate following treatment
of subfertile men with FSH is likely due to effects on other
sperm qualities (such as sperm DNA fragmentation (sDF), see
below) or on testicular functions leading to an improvement
of sperm functions necessary for the process of fertilization
which are not evaluated by routine semen analysis (such as
hyperactivation motility, ability to undergo acrosome reaction
or increased chromatin compaction). In this respect, a recent
study (23), demonstrated that treatment with FSH improves the
percentage of spermatozoa able to bind hyaluronic acid in FSH
responding men (i.e., men increasing total sperm count and
total motile sperm count after FSH treatment). As ability to
bind hyaluronic acid is indicative of higher sperm maturation
(24), the study by Casamonti et al. (23) suggests that FSH
may improve such testicular function. Alterations in sperm
maturation process are also involved in the generation of sDF (see
below).
This review focuses on the effect of FSH administration to
idiopathic infertile men on sperm DNA fragmentation levels,
discussing the possible mechanisms involved in the action of the
hormone.
Sperm DNA Fragmentation (sDF)
The main function of spermatozoa is to deliver DNA to the
oocyte at fertilization. Integrity of sperm and oocyte DNA is
fundamental for development and quality of embryos. Sperm
DNA integrity is often compromised in infertile men and sDF
represents the most common DNA abnormality in these men
(25). sDF consists in the presence of single and double DNA
strand breaks in the sperm nucleus. Such breaks may occur
at different levels of the sperm’s life, virtually from early steps
of spermatogenesis to the site of fertilization. Indeed, there is
evidence that sperm DNA breaks may originate in the testis,
in the epididymis, during transit in the ejaculatory ducts,
following ejaculation and even during in vitro manipulation
for ARTs. Many types of insults have been demonstrated to
provoke DNA breaks, which act through two main pathways:
an apoptotic process, leading to activation of endonucleases and
a direct attack to DNA by free radicals which produces both
base oxidation and strand breaks (26). The apoptotic process
occurs mainly during spermatogenesis, either because of insults
impairing the testicular function or because of a derailment of the
chromatin condensation process during spermiogenesis (27, 28).
Spermatozoa with apoptotic signs (including DNA breaks) are
found in the ejaculate because the apoptotic process fails to
complete [abortive apoptosis, (29)]. Although free radicals, at
low levels, play an important role for sperm functions [such as
motility and capacitation (30)], when ROS production overtakes
the anti-oxidant defenses of spermatozoa several damages can
be produced (31). Excessive ROS production may act virtually
at any level during sperm’s life (32), although evidence suggests
that their action occurs mostly after spermiation (see below)
and even during in vitro manipulations for ARTs (33, 34). The
occurrence of defects in the process of chromatin compaction
renders the spermatozoa particularly vulnerable to ROS attack
(35). Muratori et al. (28) has recently reported that a clear
overlapping between oxidative damage and DNA breaks was
detected only in viable spermatozoa, whereas in the bulk of
ejaculated spermatozoa (including viable and non-viable cells
and where most DNA fragmented spermatozoa are non-viable)
the presence of DNA breaks overlapped highly apoptotic traits.
Considering that viable, DNA fragmented spermatozoa are
cells where DNA damage developed more recently respect to
the ejaculation (28), these results suggest that oxidative stress
acts later in sperm’s life, most likely during transit in the
male genital tract, whereas apoptotic damage occurs earlier,
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mainly at testicular level. A recent clinical study (36) seems
to confirm such hypothesis revealing that sDF in unviable
spermatozoa is associated mainly with the presence of ultrasound
signs of testicular abnormalities, whereas the DNA fragmented
sperm population containing viable spermatozoa was mostly
associated with clinical and ultrasound alterations of the prostate
and of seminal vesicles, likely due to inflammatory statuses.
There is also evidence that DNA damage may occur after
ejaculation during in vitro incubations (37–39) or because
of in vitro manipulation during sperm selection for ARTs
(33, 34, 40). In the latter case, DNA fragmented spermatozoa
are highly motile and the damage appears to be induced
by the contamination with heavy metals of density gradient
preparations (33). Viable sperm with oxidative damage and/or
strand breaks in their DNA are, most likely, a very dangerous
sperm fraction of the ejaculate: they can actively participate
in the fertilization process and give rise to embryos unable to
successfully develop if the oocyte does not or only partially
repairs the damage.
Many studies (41–43) reported that high levels of sDF are
associated with a decrease of natural male fertility and recent
meta-analyses confirmed the negative relationship between the
amount of sDF and the outcomes of natural or assisted
reproduction (44–46). It should be noted that important
differences exist among the studies on ART outcomes, especially
regarding couple inclusion criteria and methods used to evaluate
sDF. Indeed, sDFmay be evaluated by several methods [reviewed
in (47)], among which TUNEL (Terminal deoxynucleotidyl
transferase dUTP nick end labeling), COMET (also known
as single-cell gel electrophoresis), SCSA (Sperm Chromatin
Structure Assay) and Halosperm assays are the most popular.
The problem with these methods is that they likely detect
different types of DNA damages (47). In addition, these
methods (with the exception of SCSA) are not standardized,
thus making difficult to compare results among the studies.
Recent meta-analyses grouped the studies according to the
methods used to evaluate sDF and reported consistently
that TUNEL and COMET methods are those that better
reveal the negative association between sDF and pregnancy
rate after ARTs (45, 46). TUNEL also resulted the method
that better reveals the impact of sperm DNA damage on
miscarriage in couples who conceived naturally or after IVF and
ICSI (44).
Overall, the bulk of the studies described above suggests that
sDF represents a target to treat men with idiopathic infertility.
In consideration that apoptosis and oxidative stress are the
main mechanisms producing DNA strand breaks (see above)
possible therapies to prevent or decrease sDF are antioxidants
and anti-apoptotic agents. The former have been used in
several clinical studies, but, so far, reported beneficial effects
are minimal. Indeed, a recent Cochrane meta-analysis (48)
could not draw definitive conclusions regarding the benefit
of treatment with anti-oxidant on live birth rates for infertile
couples as only four low quality small randomized controlled
trials were published at that time. The same meta-analysis
reported also data about the effect of antioxidants on sDF
levels. Even in this case, no clear conclusions could be drawn
because the two trials included in the meta-analysis utilized
different antioxidants in a low number of patients (48). Use
of anti-apoptotic agents, on the other hand, is not feasible
because of the ubiquitous role of programmed cell death in the
body. A notable exception is represented by FSH which has
specific anti-apoptotic (or pro-survival) effects at testicular level
(49–52).
Effect of Treatment With FSH on sDF
Levels
A recent meta-analysis evaluated the effect of FSH on SDF
(53) including six studies with overall 383 men with idiopathic
infertility treated with FSH. The meta-analysis revealed a slight
but significant decrease of sDF after FSH treatment for 3
months but not of other semen parameters such as sperm
concentration, motility and morphology. Of note, the studies
included in the meta-analysis are extremely heterogeneous, both
for inclusion criteria and FSH treatment scheme. Indeed, in
three of them patients with severe oligozoospermia (54) or
oligoasthenoteratozoospermia (15, 55) were included, in another
(56), patients with at least one parameter below the WHO
criteria, whereas in the paper by Garolla et al. (57) male partners
of infertile couples with any kind of infertility cause (with
exclusion of seminal tract infections and antisperm antibodies)
were included if sperm count was above 20 millions. The only
study where sDF basal levels (at the cut-off level >15%) were
comprised in the inclusion criteria was that of Simoni et al. (6).
Interestingly, Ruvolo et al. (55), demonstrated that patients with
sDF levels >15% were those showing a significant reduction
in DNA sperm damage. More recently, Colacurci et al. (58)
published results of a multicentric longitudinal trial including
103 infertile men treated with FSH for 3 months: the study
demonstrated a slight but significant effect of the hormone
on average sDF levels. Interestingly, this study evidenced that
the treatment was more effective in the 48 patients showing
sDF levels above 17% (median value of the caseload) and
demonstrated that lifestyle habits like smoking may decrease
the effectiveness of the therapy. The clinical studies included
in the meta-analysis of Santi et al. (53) were heterogeneous
also regarding the treatment schemes (type and dosage of FSH
used) and the methods used to evaluate sDF, even if most
studies employed TUNEL assay (6, 15, 54, 55, 57). It should be
considered that TUNEL is not a standardized method and it has
been reported that even small variations in the different steps
of the assay may affect greatly the measures (59). In addition,
an important difference regards the detection method: TUNEL
positive spermatozoa may be evaluated by flow cytometry in
thousands of spermatozoa [as used in the papers by (57) and (6)]
or by fluorescence microscopy in few hundreds of spermatozoa
[used in (15, 54, 55)]. Discrepancies between the two detection
methods are due not only to the different number of analyzed
cells but also to the different sensitivity of the procedures. For
these reasons, comparison of studies employing flow cytometry
or fluorescence microscopy revealed that the former yields
greater measures of sDF (60). This methodological issue can
explain why the meta-analysis of Santi et al. (53) failed to find
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FIGURE 1 | Main possible mechanisms of FSH reducing effect on sperm DNA fragmentation levels, and supporting literature for each pathway. Straight lines:
pathways demonstrated in testis or in vitro testicular cells; dotted lines: hypothesized pathway (as demonstrated to occur in pre-ovulatory follicules in vitro).
a difference in the average sDF levels after treatment when
comparing FSH treated and untreated men.
There is also evidence, in the literature, that specific genotypes
of FSHR (the polymorphism p.N680s) predicts responsiveness to
FSH administration (6) and that the polymorphism of FSH beta-
subunit promoter FSHB-211 TT is associated with lower FSH
levels and lower sperm counts (61). Overall these studies suggest
that the use of pharmacogenetic approaches to select patients,
may increase the percentage of responders to the therapy.
Clearly, larger studies are needed to confirm the ameliorative
effect of FSH on sDF: such studies should be properly designed,
possibly using selection criteria which include a cut-off of
sDF basal levels and the above mentioned pharmacogenetic
approaches. However, it must be mentioned that, due to
lack of international standardized procedures to evaluate sDF,
identifying a cut-off value depends strictly on the assay used to
measure the parameter. At present, the only possibility is the
identification of cut-off values by comparing fertile and infertile
subjects in each laboratory using the chosen method to evaluate
sDF among those currently available (see above).
Which is(are) the mechanism(s) through which FSH
ameliorates sDF levels in the ejaculate? If we consider that
most DNA fragmented spermatozoa show signs of apoptosis
and chromatin immaturity (28) likely due to a derangement of
the spermatogenetic process or of the chromatin maturation
process, the most probable mechanisms of action of FSH consist
in anti-apoptotic and maturation promoting effects at tubular
level. There is evidence of anti-apoptotic effects of FSH both
in the ovary and in the testis. In the ovary, the hormone is
a major survival factor for follicles (62) and antagonizes the
apoptosis induced by oxidative stress reducing ROS production
through stimulation of the antioxidant glutathione (GSH)
(63). In the testis, suppression or immunoneutralization of
FSH increases apoptotic DNA fragmentation (49–51, 64). FSH
suppression induces spermatogonial apoptosis predominantly
via the intrinsic pathway, as an increase of caspase activity
(52) and a decrease of BCL2 (51) have been demonstrated in
spermatogonial cells. Consistently, in vitro studies demonstrated
up-regulation of the BCL2 family member Bcl2l2 mRNA in
spermatogonia of adult mice after FSH treatment (65). However,
the molecular details by which FSH deprivation leads to
activation of the apoptotic intrinsic pathway in spermatogonia
is not fully clarified. In a murine model, upon deprivation of
gonadotropins, the initiation of apoptosis was preceded by p38
MAPK activation and induction of iNOS (66) and this seems to
be the case also in normal adult men (51, 52). FSH anti-apoptotic
effects seems to occur both in Sertoli cells and in germ cells (64)
and, in the latter, both before and after meiosis (49, 50, 64).
Interestingly, it has been shown that the mechanisms by which
gonadotropins promote the survival of germ cells can be
different depending on the cell type (51, 52). In Sertoli cells, FSH
promotes anti-apoptotic pathways presumably trough activation
of protein kinase B/AKT protein (67). These results suggest that
FSH may regulate proliferation and development of male germ
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cells both indirectly, by acting on Sertoli cells, and directly by
up-regulating anti-apoptotic pathways in germ cells. There is
also evidence for an effect of FSH on sperm maturation. Baccetti
et al. (68) reported an improvement of semen quality and
ultrastructural characteristics of spermatozoa in men with high
levels of apoptosis and immaturity features in their spermatozoa,
supporting the anti-apoptotic and pro-maturation role of
FSH in human testis. Recently, a role of FSH favoring sperm
maturation has been suggested by the above mentioned study of
Casamonti et al. (23), which demonstrated that FSH increases the
number of spermatozoa binding to Hyaluronic acid. Although
the mechanism(s) through which FSH may promote sperm
maturation are mostly unknown, interestingly, a disturbance
in the normal replacement of histones by protamines during
spermiogenesis, leading to poor condensation of spermatid
nuclei, has been demonstrated in FSHR KO mice (69). Sperm
maturation is closely linked to DNA integrity. Indeed, it is during
spermiogenesis that the replacement of histones with protamines
occurs and, as mentioned, a derangement of this process may
lead to DNA fragmentation due to lack of re-ligation of the
nicks necessary for chromatin compaction (70, 71). In addition,
there is evidence that a disturbance of the process of chromatin
compaction can represent a trigger for induction of apoptosis
in the testis (28). Finally, increased ability of sperm to bind
to hyaluronic acid has been associated to higher chromatin
compaction and decreased DNA fragmentation (24, 72).
As mentioned above, DNA damage can be produced also by a
direct attack of ROS. Although, at present, there is no evidence
of an anti-oxidant effect of FSH in the testis or in spermatogonial
cells in vitro, such effect of the hormone cannot be excluded, as it
reduces oxidative stress-induced apoptosis in ovarian cells (63).
It should be mentioned that oxidative stress may produce the
formation of breaks and stable DNA adducts also through a direct
attack to DNA (31) and that such damage could persist following
FSH treatment. The main possible mechanisms of FSH-related
decrease of sDF levels are summarized in Figure 1.
CONCLUSION
Although sDF is an important reproductive problem affecting
the outcomes of both natural and assisted reproduction, effective
treatments to prevent or limit the sperm DNA damage in men
are presently scarce. Treatment with FSH appears promising as
there is evidence of a beneficial effect of the treatment on sDF
(53). However, the lack of clear and univocal patient inclusion
criteria contributes to the high heterogeneity of the clinical
studies published so far, which does not allow to draw clear-cut
conclusions about the effectiveness of the hormone on sperm
DNA damage. Future studies should not only include cut-off
values of sDF among patient inclusion criteria but also consider
the pharmacogenetic evidence of FSH action to identify subjects
that may not have beneficial effects from the therapy.
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